Hypoxic regions are frequent in glioblastoma (GBM), the most common type of malignant adult brain tumor, and increased levels of tumor hypoxia have been associated with worse clinical outcomes. To unmask genes important in hypoxia, we treated GBM neurospheres in hypoxia and identified monocarboxylate transporter-4 (MCT4) as one of the most upregulated genes. To investigate the clinical importance of MCT4 in GBM, we examined clinical outcomes and found that MCT4 overexpression is associated with shorter patient survival. Consistent with this, MCT4 upregulation correlated with the aggressive mesenchymal subset of GBM, and MCT4 downregulation correlated with the less aggressive G-CIMP (Glioma CpG Methylator Phenotype) subset of GBM. Immunohistochemical analysis of tissue microarrays confirmed that MCT4 protein levels were increased in high-grade as compared with lower-grade astrocytomas, further suggesting that MCT4 is a clinically relevant target. To test the requirement for MCT4 in vitro, we transduced neurospheres with lentiviruses encoding short-hairpin RNAs (shRNAs) against MCT4, resulting in growth inhibition of 50-80% under hypoxia in two lines. MCT4 knockdown was associated with a decreased percentage of cells expressing the stem-cell marker CD133 and increased apoptotic fraction. We also found that flow-sorted CD133-positive cells had almost sixfold higher MCT4 levels than CD133-negative cells, suggesting that the stem-like population might have a greater requirement for MCT4. Most importantly, MCT4 silencing also slowed GBM intracranial xenograft growth in vivo. Interestingly, whereas MCT4 is a well-characterized lactate exporter, we found that both intracellular and extracellular lactate levels did not change following MCT4 silencing, suggesting a novel lactate export-independent mechanism for growth inhibition in GBMs. To identify this potential mechanism, we performed microarray analysis on control and shMCT4-expressing neurospheres and found a dramatic reduction in the expression of multiple Hypoxia-Inducible Factor (HIF)-regulated genes following MCT4 knockdown. The overall reduction in HIF transcriptional response was further validated using a hypoxia response element (HRE)-dependent green-fluorescent protein (GFP) reporter line.
INTRODUCTION
Glioblastoma (GBM) are the most frequent malignant brain tumors in adults but are still incurable; thus, new therapeutic targets and improved treatments are needed. These neoplasms frequently exhibit tumor hypoxia and high glycolytic rate. 1 Signaling pathways such as Hedgehog, Notch, and WNT have been discovered to have major roles in the proliferation and survival of primitive, stem-like GBM cells. [2] [3] [4] [5] [6] [7] [8] [9] [10] Work done by our group and others has established that stem-like GBM cells favor low oxygen levels and are typically found in the hypoxic tumor core [11] [12] [13] [14] [15] [16] (and reviewed in Bar 17 and Heddleston et al. 18 However, although it is clear that Hypoxia Inducible Factor -1 and -2 alphas (HIF1a and HIF2a) are intimately involved in the induction of stem-like phenotype under hypoxia, factors facilitating this critical phenotypic change are still unknown.
We investigated the role of the monocarboxylate transporter-4 (MCT4) in malignant gliomas for several reasons. First, MCT4 levels are greatly induced in the stem-cell-rich hypoxic microenvironment of GBMs. Second, MCTs have been linked to the regulation of glycolytic metabolism, 19 and glycolytic metabolism is crucial for the expansion of neoplastic as well as non-neoplastic stem cells. [11] [12] [13] 17, 18, [20] [21] [22] [23] [24] [25] MCT4 is one of four proton-linked MCTs. Expression patterns of MCTs vary with cell type. For example, whereas MCT1 is expressed primarily in endothelial cells, MCT4 is expressed mainly in astrocytes. Neurons, on the other hand, express primarily MCT2. With relevance to cancer, MCT4 overexpression has been reported in several solid tumors, including metastases of breast cancer to the brain, suggesting that this class of transporters may be associated with aggressive tumor behavior. 26 As MCT4 is a critical component in glycolytic metabolism, and such metabolism is utilized in non-neoplastic neural stem cells, 21 we hypothesized that neoplastic stem-like cells may be susceptible to MCT4 inhibition. The potential utilization of MCT1 inhibition as an anti-GBM therapeutic approach has been explored using adherent, high serum-propagated cells. [27] [28] [29] [30] [31] [32] However, the role of HIF1a-regulated 33 MCT4 in GBMs including stem-like tumor cells is yet to be investigated.
In this study, we demonstrate that MCT4 expression is associated with increased World Health Organization glioma grade and inversely correlate with overall survival of GBM patients. In addition, based on the recent subgroup classification of GBMs, tumors that are classified as 'mesenchymal' are more aggressive and express higher levels of MCT4. MCT4 appears to regulate proliferation, survival and xenograft implantation/growth of some GBM neurosphere lines. Furthermore, we found that suppression of MCT4 using short-hairpin RNA (shRNAs) results in a dramatic downregulation of multiple HIF1a transcriptional targets. These effects appear to be independent of lactate homeostasis and provide a potential mechanism by which MCT4 may regulate stem-like phenotype and the hypoxic response driven by HIF and thus represents a novel therapeutic target in GBMs.
RESULTS

MCT4 is overexpressed in hypoxic
GBMs and is associated with poor clinical outcome Our group and others have previously shown that hypoxia induces stem-like characteristics in GBM neurospheres and that inhibition of HIF1a, a master transcriptional regulator of the hypoxic response, reversed the effects of hypoxia and led to decreased clonogenicity and growth in vitro and tumor formation in vivo. 11, 12, 14, 16 Microarray analysis was subsequently performed on HSR-GBM1 and JHH-GBM10 GBM neurosphere lines grown under normoxia (21% oxygen) or hypoxia (1% oxygen) for 24 h. We identified MCT4 (also known as SLC16A3) as one of the top 10 most upregulated genes in response to hypoxia (Figure 1a , SLC16A3 highlighted in green). We hypothesized that as the only MCT transcriptionally upregulated under hypoxia (transcription of other MCTs were either unchanged or even downregulated, data not shown), it might have a critical role in therapy-resistant stem-like cell survival and that inhibition of MCT4 would target GBM tumor growth.
We first examined the levels of MCT4 in GBM patients. Figure 1b shows gene-expression data collected from the gene expression omnibus database of various glioma grades. We found that MCT4 mRNA is significantly overexpressed in Grade IV gliomas compared with normal brain Grade II and Grade III gliomas (Figure 1b) . To determine whether this difference in expression is also present at the protein level, we performed immunohistochemical analysis on tissue microarrays of grades II, III and IV gliomas. Semiquantitative analysis of MCT4 immunoreactivity confirmed that MCT4 is overexpressed in GBM when compared with lower-grade gliomas (Figure 1c) . Indeed, overexpression of MCT4 may be a GBM-specific phenomenon as normal brain cores were always negative (data not shown).
We also found that MCT4 was most highly expressed in GBM tumors distal to blood vessels in regions generally associated with hypoxia. This latter finding is in agreement with our in vitro data that MCT4 is overexpressed under hypoxia (representative core shown in Figure 1c ). As increased intratumoral hypoxia has been linked to decreased survival in GBM patients, 34 we hypothesized that as a surrogate marker of hypoxia MCT4 may also predict survival. Examination of GBM patient-survival data in REMBRANDT (https:// caintegrator.nci.nih.gov/rembrandt/) revealed that MCT4 level is inversely correlated with the survival of GBM patients (Figure 1e , logrank survival test, Po0.05). Furthermore, examination of MCT4 expression levels within the GBM subgroups described by Verhaak et al. 35 strongly suggested that MCT4 is overexpressed primarily in the most aggressive mesenchymal subclass (Supplementary Figure  S1) . Finally, using the same The Cancer Genome Atlas data set, we found that MCT4 is overexpressed primarily in the non-G-CIMP (Glioma CpG Island Methylator Phenotype) tumors, which have traditionally been associated with worse outcome than the G-CIMP subgroup (Supplementary Figure S2) . Taken together, these data indicate that MCT4 is overexpressed in hypoxic GBMs and is associated with aggressive tumor behavior.
MCT4 levels increase in hypoxic GBM neurospheres To confirm the induction of MCT4 under hypoxia, we exposed HSR-GBM1, JHH-GBM10 and JHH-GBM14 neurospheres to normoxia and hypoxia in vitro and quantitated MCT4 mRNA levels using quantitative real-time PCR. We found that MCT4 mRNA levels increased over time, reaching maximal levels after 20 h in HSR-GBM1 and 48 h post exposure to hypoxia in JHH-GBM10 and JHH-GBM14 (Figures 2a-c, dark gray bars) . These data are consistent with an earlier report showing that MCT4 is under direct HIF1a transcriptional regulation. 33 Interestingly, the increase in MCT4 mRNA levels over time was not limited to hypoxia. We measured significant increases even in normoxia, with maximal induction seen 48 h after plating cells in fresh medium, suggesting that cell density may also have a role in MCT4 induction (Figures 2a-c, clear bars). To measure MCT4 protein levels, we performed western blot analysis on neurospheres exposed to normoxia or hypoxia for 0, 2, 4 and 5 days. Consistent with the mRNA data, MCT4 protein levels increased rapidly, reaching maximal levels 48 and 96 h in HSR-GBM1 neurospheres exposed to hypoxia and normoxia, respectively (Figure 2d ). Thus, MCT4 protein and mRNA levels increase not only in response to hypoxia but also in normoxia, as cultures become more confluent. In two additional lines, JHH-GBM10 and JHH-GBM14, we found significant increases in MCT4 levels following 48 h of hypoxic treatment (Figure 2e ). Interestingly, JHH-GBM10 had high baseline MCT4 mRNA and protein levels even under normoxia, which further increased under hypoxia, suggesting that normoxic expression of MCT4 varies with cell line and may potentially indicate the difference in dependency. U87-MG protein lysate was used as a loading control, as this line expresses MCT4 constitutively.
MCT4 plasma membrane localization is tightly regulated by its association with the plasma membrane glycoprotein CD147 (Basigin); 36 we therefore examined MCT4 subcellular localization in response to hypoxic treatment. To this end, we immunostained cytospun neurospheres pre-exposed to either normoxia or hypoxia for MCT4 (Figure 2f ). Under normoxia, the MCT4 protein (red fluorescence) was barely detectable in HSR-GBM1 and JHH-GBM14 cells. Consistent with the western blot analysis (Figure 2e ), we detected high basal level of the MCT4 protein in normoxic JHH-GBM10, much of which was associated with the plasma membrane ( Figure 2f ). Additionally, the immunofluorescence staining suggests that MCT4 localization to the cell membrane increased under hypoxia (Figure 2f , lower panels). Taken together, these data suggest that MCT4 is induced at the mRNA and protein levels by hypoxia and that it can also accumulate to a lesser degree in a time-/cell density-dependent manner in normoxia. Induction of MCT4 results in increased localization at the plasma membrane, the site it is expected to function as a MCT.
Reduction in MCT4 levels results in the induction of apoptosis and reduced cell proliferation The dramatic induction in most neurosphere lines of MCT4 in response to hypoxia suggests that it might be critical for the proliferation and/or survival of GBM cells in reduced oxygen. Indeed, several reports have been recently published implicating another MCT, MCT1, in the survival of adherent, high-serumconditioned GBM cell lines. [27] [28] [29] [30] [31] [32] To test the possibility that MCT4 may be required in stem-like GBM neurospheres, we transduced HSR-GBM1 (which has low levels of MCT4 under normoxia) and JHH-GBM10 (which has high levels of MCT4 under normoxia, Figure 2e ) with viruses encoding shRNAs targeting MCT4. Two independent shRNA constructs were used (sh1 and sh2), both of which resulted in significant reduction in MCT4 levels of up to 90% in HSR-GBM1 (Supplementary Figure S3A) . Despite multiple rounds of transduction, we could not obtain a stable, proliferating culture of JHH-GBM10 expressing these same shRNA constructs, suggesting more severe negative effects on growth in this line.
To circumvent this hurdle, we cloned an shRNA sequence against MCT4 (sh1) into conditional pLKO-Tet-ON inducible vector (Novartis Developmental and Molecular Pathways, Cambridge, MA, USA, through http://www.Addgene.org). Neurospheres were expanded in the absence of tetracycline to keep the levels of MCT4 high enough to allow cultures to be expanded. In all further experimentations using this inducible construct, we did not include tetracycline in the growth medium, as we found this to be unnecessary. The 'leaky' shRNA cassette provided pronounced mRNA knockdown (an over 90%, statistically significant reduction by Student's t-test) and appeared to inhibit cell growth without completely killing the cultures (Supplementary Figure S3B) .
To quantify the effects of MCT4 knockdown on growth, we performed MTS assays on HSR-GBM1 and JHH-GBM10 neurospheres expressing either control or shMCT4 constructs. We found that MCT4 silencing resulted in significant growth inhibition in HSR-GBM1 (Figures 3a and b ; normoxia, hypoxia) and JHH-GBM10 (Figures 3c and d ; normoxia, hypoxia) under both normoxic and hypoxic conditions. One potential caveat to the MTS/MTT assay is its dependency on mitochondrial dehydrogenase activity, as oxygen is a major effector of mitochondrial activity. We therefore also performed viable cell counts using the Guava PCA flow cytometer. Consistent with the MTS assays, MCT4 inhibition using sh1 and sh2 resulted in a significant growth inhibition in HSR-GBM1 neurospheres grown for 5 days under normoxia and hypoxia ( Supplementary Figures S4A and B) . Whereas both HSR-GBM1 and JHH-GBM10 showed clear growth inhibition following shMCT4 virus transduction, two additional neurosphere lines, HSR-040622 and HSR-040821, showed less pronounced growth effects following MCT4 inhibition (data not shown). We therefore focused our studies on HSR-GBM1 and JHH-GBM10.
We next attempted to elucidate the mechanism by which MCT4 inhibition affects proliferation. First, we performed cell cycle analysis of normoxic and hypoxic neurospheres. We could not detect any clear difference in cell cycle fractions in HSR-GBM1 under normoxic or hypoxic conditions (data not shown). However, we identified significant increases in sub-G1 (G0) fractions in normoxic (0.5% in control to 3.1% and 5.6% in sh1-and sh2-expressing cells, respectively) and hypoxic (1.2% in control to 11% and 6.4% in sh1-and sh2-expressing cells, respectively) neurospheres (Figure 3e ). These data suggest that reduced MCT4 levels may lead to induction of apoptosis. To further quantitate the apoptotic fraction, we performed Annexin-V assays on normoxic and hypoxic neurospheres expressing either control or the sh1 or sh2 constructs. We found that under normoxia, MCT4 silencing by both shRNAs resulted in at least a 1.8-fold increase in the apoptotic fractions, from 9.6% in controls to 18% and 21% in sh1 and sh2, respectively. Under hypoxia, apoptotic fractions increased from 12.4% to 23% and 26% in sh1 and sh2, respectively. These inductions were statistically significant as determined by one-way analysis of variance (ANOVA) analysis (Po0.0001) (Figure 3f ).
Stem-like CD133-positive cells are sensitive to MCT4 inhibition The dramatic induction of MCT4 under hypoxia and the significant growth inhibition we observed following MCT4 inhibition prompted us to investigate a potential requirement for MCT4 in stem-like GBM cells, as we have previously shown that hypoxia induces stem-like characteristics in GBM. 12 HSR-GBM1 and JHH-GBM10 were FACS-sorted into CD133-positive and -negative fractions followed immediately by quantitative real-time PCR analysis (Figures 4a and b) . We found that normoxic, stem-like CD133-positive fractions in both HSR-GBM1 and JHH-GBM10 cultures expressed significantly higher levels of MCT4 mRNA compared with the CD133-negative fractions. The difference between the fractions was greatest in HSR-GBM1, with an almost sixfold induction (Student's t-test, P ¼ 0.0016 and P ¼ 0.0019, respectively) ( Figures  4a and b) . These results suggest that there might be a greater requirement for MCT4 in CD133-positive stem-like cells as compared with CD133-negative cells and that this requirement may not be limited to growth under hypoxic conditions.
We next quantitated CD133-positive fractions using flow cytometry following MCT4 silencing in HSR-GBM1 and JHH-GBM10. Consistent with our previous report, the percentage of CD133-positive cells increased following hypoxic treatment of HSR-GBM1 (Figures 4c and d) . In JHH-GBM10, the majority of cells expressed CD133 under normoxic conditions, and these levels did not change significantly upon hypoxic treatment (Figures 4e and  f) . Importantly, we found that CD133-positive fractions were sharply reduced following MCT4 silencing in both HSR-GBM1 and JHH-GBM10. CD133-positive fractions decreased from 49% in control to 40% in sh1 expressing normoxic and from 63% to 37% in hypoxic HSR-GBM1 cells, respectively (Figures 4c and d) . In JHH-GBM10, we recorded the most dramatic reduction in CD133-positive fractions from 82% to 1.4% and from 78% to 5.33% under normoxia and hypoxia, respectively, for sh1 (Po0.0001 by oneway ANOVA and Student's t-test, respectively).
Finally, we also examined the expression of Nestin, another marker routinely used to mark stem-like GBM cells. We found that similar to CD133, Nestin expression nearly halved in HSR-GBM1 following MCT4 silencing (Figure 4g ). Additionally, Nestin expression was nearly extinguished (over 90% reduction) in JHH-GBM10 (Figure 4h ), mirroring the dramatic reduction in CD133 fraction in this neurosphere line (Figures 4e and f) .
The effects of MCT4 inhibition are not associated with alterations in lactate levels As the most noted activity of MCT4 is passive exportation of lactate across the plasma membrane, we next explored the possibility that inhibition of growth and the reduction in the stemlike subpopulation may be because of reduced lactate secretion. To this end, we measured extracellular lactate levels in control and shMCT4-expressing HSR-GBM1 and JHH-GBM10 cells. As expected, extracellular lactate levels almost doubled when control HSR-GBM1 cells were grown under hypoxic conditions, increasing from 2.8 to 4.5 mM (Figure 4i ). In JHH-GBM10, extracellular lactate levels more than doubled, increasing from 0.6 to 2.6 mM (Figure 4j) . Interestingly, we found no significant reduction in extracellular lactate levels in HSR-GBM1 and a significant increase in lactate levels in JHH-GBM10 following MCT4 inhibition (Figures 4i and j) . To further investigate this, we also examined intracellular lactate levels and found no significant changes between control and shMCT4-expressing cells (not shown). One potential explanation for the increase in extracellular lactate levels in JHH-GBM10 (Figure 4j , compare gray bars) may be an increase in the expression of MCT1. Indeed, we found that MCT1 mRNA levels more than tripled following MCT4 inhibition in JHH-GBM10 (Supplementary Figure S5) . These data strongly suggest that lactate homeostasis did not have a significant role mediating the various cell phenotypes noted above.
MCT4 inhibition suppresses HIF transcriptional activity
To obtain further insight into the potential mechanism by which MCT4 downregulation may inhibit cell proliferation and stem-cell properties, we performed microarray analysis on HSR-GBM1 cells expressing control or shRNA against MCT4 (sh1 and sh2). Excitingly, we found that multiple known HIF1a transcriptional targets, such as NDRG1, STC2, CAIX and LOX, [37] [38] [39] [40] were dramatically downregulated in HSR-GBM1-expressing shMCT4 as compared with control HSR-GBM1 cells (Figure 5a ). In addition, we found that WISP2, a known HIF2a target, is greatly downregulated as well, suggesting that HIF2a transcriptional activity might also be inhibited. 41 We found that additional known HIF1a targets such as PLOD1, VEGFA, ENO1, PGK1 and ALDOA were also significantly downregulated but to a lesser degree (data not shown). Next, we validated these results by directly measuring relative expression levels of several known direct HIF1a transcriptional targets using quantitative real-time PCR analysis in HSR-GBM1 and JHH-GBM10 neurospheres expressing shRNA against MCT4 (sh1) or control. We found that VEGFA was inhibited by 36% in HSR-GBM1 sh1 and by 95% in JHH-GBM10 sh1. Similarly, LOX was inhibited by 81% in HSR-GBM1 sh1 and by 87% in JHH-GBM10 sh1, and CAIX was inhibited by 55% in HSR-GBM1 sh1 and almost completely extinguished in JHH-GBM10 sh1 (Figure 5b ). Significant reduction in these genes was also observed with a second shRNA construct against MCT4 (sh2) in HSR-GBM1 (data not shown).
The reduction in the transcript levels of individual HIF1a targets (Figure 5a ) prompted us to examine the overall effects of silencing MCT4 on HIF transcriptional activity. To this end, we generated HSR-GBM1 neurospheres expressing an integrated hypoxia response element (HRE)-destabilized green-fluorescent protein (GFP) construct in addition to a constitutive dsRed driven by the UbC promoter (named HSR-GBM1 G6D). Following transduction with shRNAs targeting MCT4, we exposed cells to either normoxia or hypoxia for 48 h and evaluated overall HIF transcriptional activity using flow cytometry. As seen in Figure 5c , hypoxia increases the percentage of GFP-positive cells from 13.2 to 81.5% in control. In contrast, the percentage of GFP-positive cells was significantly reduced to 62.4% and 59.5% in sh1 and sh2 expressing HSR-GBM1 G6D reporter cells, respectively (one-way ANOVA, *** Po0.001). These data represent a 70 and 50% reduction in the relative HIF transcriptional reporter activity in hypoxia for sh1 and sh2, respectively. Importantly, these dramatic changes in HIF1a activity are most likely because of reduced transcriptional activity, as overall HIF1a protein levels remained unchanged (not shown). Taken together, these data strongly suggest that MCT4 downregulation significantly inhibits HIF transcriptional activity.
MCT4 silencing results in growth inhibition in vivo
We have previously shown that in glioma, hypoxia induces expansion of the stem-like population 12 and that therapies targeting stem-like cells prevent tumor engraftment and longterm growth. 2, 8, 12, 42 The dramatic reduction in the expression of HIF1a target genes and the stem-like population in HSR-GBM1 and JHH-GBM10 following MCT4 inhibition in vitro prompted us to evaluate the potential effects of MCT4 downregulation in vivo. HSR-GBM1 neurospheres were transduced with either control or shMCT4 viruses before intracerebral implantation of 1 Â 10 5 viable cells (seven animals in control, eight animals in sh1 and five animals in sh2). Xenografts were allowed to grow for B4 months followed by histological analysis of the resulting tumors (Figures 6a-d) . We found that sh1 MCT4-and sh2 MCT4-expressing cells formed significantly smaller tumors as compared with cells transduced with control virus (Student's t-test, P ¼ 0.0013) (Figure 6e ). In addition, it appeared that shMCT4-expressing cells formed tumors that were less invasive (Figures  6a and c) .
DISCUSSION
In this study, we have shown that the proliferation and survival of GBM stem-like cells are dependent on the MCT4. We first demonstrated that hypoxia dramatically induces MCT4 expression (c) MCT4 downregulation results in significant reduction in the stemlike CD133-positive cell population in both HSR-GBM1 (from 49 to 40%, normoxia (c), and from 63 to 37%, hypoxia (d)) and JHH-GBM10 (from 82 to 1.4%, normoxia (e), and from 78 to 5.33%, hypoxia (f )). (g) Reduction in MCT4 levels, using either sh1 or sh2 reduces Nestin expression as measured using quantitative real-time PCR in HSR-GBM1 (g) and JHH-GBM10 (h). (i) Extracellular lactate levels are induced under hypoxic conditions (compare filled to clear bars) in both HSR-GBM1 (i) and JHH-GBM10 (j). However, reduction in MCT4 levels using either sh1 or sh2 does not reduce lactate levels in either normoxia or hypoxia. (one-way ANOVA (i) and Student's t-test (j); * Po0.05, ** Po0.01, *** Po0.001).
in all neurosphere cultures we tested. In addition, MCT4 overexpression is correlated with increased aggressiveness and decreased survival in GBM patients. Reducing MCT4 expression by shRNA-mediated silencing resulted in a dramatic reduction in the stem-like CD133-positive population. This gave rise to cultures with significantly reduced capacity to proliferate in vitro and to form intracranial xenografts in vivo.
We demonstrated that some GBM neurosphere cultures are extremely sensitive to MCT4 inhibition, whereas others are less affected by reduced levels of this monocarboxylate transporter. This heterogeneity underscores the notion that no single target is likely to control growth of all gliomas. It also indicates that although most GBMs share similar histological characteristics (vascular proliferation, hypoxic core, often surrounded by pseudo-palisading cells), they are likely to exhibit a range of monocarboxylates and thus metabolic dependencies. Indeed, the vast wealth of data generated by The Cancer Genome Atlas Project has confirmed that subtypes with distinct pathological molecular events and therapeutic responses exist in GBM. Our findings point to a significantly increased expression of MCT4 in the mesenchymal subtype of GBMs. These data may explain the metabolic requirement as well as drug resistance of GBMs with heightened MCT4 levels.
Finally, we examined the role of lactate in an attempt to explain the phenotypes we observed. Recent literature suggests that MCT4, with its relative low affinity for lactate (Km of B30 mM) and extremely low affinity for pyruvate (Km of B150 mM), appears to be exclusively designed for lactate efflux. 43, 44 Our results suggest Figure 5 . Expression of hypoxia-inducible genes is repressed in HSR-GBM1-expressing shRNAs targeting MCT4. Examination of the top 20 genes that are most differentially regulated in HSR-GBM1 expressing shRNAs against MCT4 as compared with the control in hypoxia, revealed that many of these genes are the direct HIF1a targets (a). Quantitative real-time PCR analysis of selected HIF1a transcriptional targets-LOX, VEGF and CAIX-confirming significant downregulation in HSR-GBM1 (left portion of graphs) and JHH-GBM10 (right side of each graph) cells expressing shRNA against MCT4 (sh1) and treated with hypoxia (b). Flow cytometric analysis of normoxic (left) and hypoxic (right) HSR-GBM1 expressing HRE-GFP (G6D) and either control or shRNAs against MCT4 (sh1 and sh2) (reference HSR-GBM1 cells are unlabeled and were used to set up the gates-black line).
that whereas growth of numerous neurosphere lines was inhibited by reduced MCT4 levels, intracellular and extracellular lactate levels remained mostly unchanged. Furthermore, we documented consistently a significant increase in extracellular levels of lactate following MCT4 inhibition in JHH-GBM10 (Figure 4j ). These results are not necessarily surprising, considering the fact that MCTs are passive transporters with redundancy between multiple MCTs. Indeed, we documented a significant increase in MCT1 mRNA levels in JHH-GBM10 expressing short hairpins against MCT4 (not shown), further supporting redundancy in lactatetransport activity. Chiche et al. 45 showed that reduced MCT4 levels resulted in intracellular acidification. This discrepancy may be explained by the fact that whereas our studies focused on GBMs, Chiche et al.
45 studied RAS-transformed fibroblasts which may differ not only by their cell of origin but also by their metabolic requirement and mechanisms of pH homeostasis. In addition, MCT4 is known to transport numerous monocarboxylates across the plasma membrane, and therefore whereas our results clearly suggest that lactate homeostasis is unaffected by MCT4 silencing, it is possible that the levels of other, yet to be characterized, monocarboxylates are more strictly dependent on MCT4 levels. Alternatively, it is possible that the catalytic activity of MCT4 is dispensable and that the effects we documented are mediated by an yet unidentified activity of MCT4. Support for the latter comes from our examination of the effects of MCT4 knockdown on global gene-expression profiles of normoxic and hypoxic neurospheres.
The identification of multiple direct HIF1a transcriptional targets in cells expressing reduced levels of MCT4 (Figure 5a ) strongly suggests that MCT4 feeds back on HIF1a activity. These results were confirmed using quantitative real-time PCR (Figure 5b) as well as by the examination of global HIF transcription using HSR-GBM1 G6D hypoxia-dependent HRE-reporter model (Figure 5c ).
Taken together, our studies suggest that MCT4 has a role in the response of stem-like GBM cells to hypoxia and that some of these effects may be independent of its role as a lactate transporter. Inhibiting MCT4 shows promise as a new therapy for GBM, particularly in stem-like and hypoxic cells. Small molecule inhibitors of various MCT family members are being developed, and our data provide a rationale for testing MCT4 inhibitors in patients with malignant gliomas. We speculate that inhibitors that will target MCT4 plasma membrane localization, via inhibition of its association with its chaperon, CD147, 36 may prove more useful than inhibitors simply targeting its transporter activity.
MATERIALS AND METHODS
GBM neurosphere lines and hypoxic conditions HSR-GBM1 (020913) was a kind gift from Dr Angelo Vescovi, and JHH-GBM10 was established from a freshly resected GBM tumor and passaged as previously described. 46 The lines were maintained in culture as originally described, and their identities confirmed at least once each year using tandem repeat analysis. A hypoxic chamber maintained at 37 1C, 1% O 2 , 5% CO 2 and 94% N 2 (COY laboratory equipment, Grass Lake, MI, USA) was used to conduct in vitro hypoxic experiments. All hypoxic experiments were conducted on cells that were plated and allowed to recover overnight before hypoxic induction.
Lentivirus preparation, concentration and transduction
Lentiviruses were produced using previously established method. 47 Briefly, MCT4 shRNA plasmids were purchased from Open Biosystems (Thermo Fisher Scientific, Huntsville, AL, USA) and packaged into lentiviral vectors by cotransfection into 293T cells with plasmids containing Gag/Pol, REV and VSV-G. Viral supernatant was harvested 24, 48, 72 and 96 h post transfection and filtered through 0.45-mm low protein-binding syringe filters. GBM neurosphere cultures were plated and transduced with viruses and then incubated at 37 1C and 5% CO 2 for a week. After 1 week, cells were put under selection with 1-5 mg/ml of puromycin (Sigma, St Louis, MO, USA) for at least a week until there were enough healthy cells to be used for experiments. Silencing of MCT4 was verified using both quantitative real-time PCR and western blot analysis.
RNA and protein analyses RNA analyses were performed by reverse transcription into complementary DNA and then quantitative real-time PCR analysis in triplicates using SYBR Green reagents (Applied Biosystems, Foster City, CA, USA; Bio-Rad, Hercules, CA, USA). To prevent amplification of genomic DNA, on-column DNase digest was performed (Qiagen RNase-free DNase kit, Qiagen, Valencia, CA, USA) during RNA extraction prior to reverse transcription. Standard curve analyses were used to determine RNA levels, and betaactin was used as a housekeeping gene for normalization. Primer sequences were as follows: MCT4 forward-5 0 -GAGTTTGGGATCGGCTA-CAG-3 0 and reverse-5 0 -CGGTTCACGCACACACTG-3 0 ; CAIX forward-5 0 -CTTGGAAGAAATCGCTGAGG-3 0 ; and CAIX reverse-5 0 -TGGAAGTAGCGGCT-GAAGTC-3 0 ; human actin-b forward-5 0 -CCCAGCACAATGAAGATCAA-3 0 ; and human actin-b reverse: 5 0 -GATCCACACGGAGTACTTG-3 0 . MCT1 primer sequences are described in Kobayashi et al. 48 Additional primer sequences are available upon request.
Protein analyses were performed via immunoblot assays using antibodies against human MCT4 (sc-50329, Santa Cruz Biotechnology, Santa Cruz, CA, USA), HIF1a (Catalog number 610959, 1:250, BD Biosciences, Franklin Lakes, NJ, USA) and b-Tubulin (Catalog number mAB5564, 1:10 000, Millipore, Billerica, MA, USA).
Flow cytometric analysis
Cells were exposed to 24 h normoxia or hypoxia and stained for CD133, then flow cytometry was performed as previously. 42 For experiments utilizing the HSR-GBM1 G6D hypoxia reporter line, cells were treated as Figure 6 . MCT4-silencing results in growth inhibition in vivo. Representative images of intracranial xenografts of HSR-GBM1-expressing control shRNA (a-b, magnification À Â 10 and Â 100, respectively) and shMCT4 (c-d, magnification À Â 10 and Â 100, respectively). (e) HSR-GBM1 transduced with either sh1 or sh2 form significantly smaller tumors as compared with cells transduced with control virus (**P ¼ 0.0013).
described above, and following dispersal to single-cell suspensions were immediately analyzed using flow cytometry without further manipulation.
Cell growth, annexin and cell cycle analyses Cell viability was assessed with an MTS assay. Cells were plated in 96-well plates and read using a plate reader 1 h after the addition of MTS reagent. Cell counts were performed using the Guava PCA machine and Guava Viacount reagent (Millipore). Annexin assays and cell cycle analyses were performed using the Guava PCA machine and Guava Cell Cycle and Nexin reagents.
Lactate assays
Cells were plated in phenol-red-free medium and allowed to recover overnight before being placed in either hypoxic or normoxic culture conditions for 24 h. For extracellular lactate measurement, conditioned media were collected. For intracellular lactate measurement, cells were pelleted and 500 ml of sterile distilled water was used to lyse each sample. Lactate assays were performed according to the manufacturer's instruction (Eton Bioscience Inc, L-Lactate Assay Kit, Eton Biosciences, San Diego, CA, USA).
Orthotopic xenograft transplantation
A total of 1 Â 10 5 shRNA-transduced HSR-GBM1 cells were stereotactically xenografted into each nude mouse: seven mice for control, eight mice for sh1 and five mice for sh2. Mice were killed after approximately two and a half months and their brains were taken out and sectioned. Sections were stained with hematoxylin and eosin, and tumor area was measured by Dr Charles Eberhart in microscopic images taken from coronal sections taken at the level of the injection site.
Immunofluorescence
Immunofluorescence staining was performed using the standard technique on GBM neurospheres incubated for 24 h either under normoxia or hypoxia then cytospun onto slides, probed with MCT4 antibody (sc-50329, Santa Cruz Biotechnology) and counterstained with 4',6-diamidino-2-phenylindole (DAPI).
Immunohistochemistry
Immunohistochemical staining was performed using the standard technique on formalin-fixed paraffin-embedded tissue sections, probed with the MCT4 antibody (sc-50329, Santa Cruz Biotechnology) and counterstained with hematoxylin.
Statistical Methods
Unless otherwise noted, in vitro and quantitative PCR data are shown as the mean values, with error bars representing s.e. of the mean for (at a minimum) three replicates, and experiments were repeated at least twice. Comparison of the mean values between groups was evaluated by unpaired, two-tailed t-test or one-way ANOVA. For all statistical methods, a P-value o0.05 was considered significant. All tests were performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).
Microarray analysis
Neurospheres were transduced with shMCT4 (Sh1 and Sh2) or control and selected for 1 week with puromycin. Then, after the removal of puromycin, cells were exposed to normoxia or hypoxia for 24 h. RNA samples were processed and analyzed using Agilent Human single color 4 Â 44 k arrays according to the manufacturer protocols. The GeneSpring GX (Agilent Technologies, Santa Clara, CA, USA) software package was used to determine expression levels using standard parameters.
Hypoxia reporter-HSR-GBM1 G6D
HSR-GBM1 cells were transfected with an HRE-GFP-d2 construct, which was a kind gift from Dr Brown Martin. 49 Following clonogenic selection of positive GFP-clones, we introduced the pLenti-UbC-dsRed-Express construct and a single clone (G6D) was selected on the basis of its ability to initiate infiltrative orthotopic xenografts in nude mice (data not shown).
